Adenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type I
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Mice lacking the enzyme fumarylacetoacetate hydrolase (FAH) have symptoms similar to humans with the disease hereditary tyrosinemia type I (HT1). FAH-deficient mice were injected with a first-generation adenoviral vector expressing the human FAH gene and followed for up to 9 months. Nontreated FAH mutant control mice died within 6 weeks from fulminant liver failure, whereas FAH adenovirus-infected animals survived until sacrifice at 2–9 months. Nine of 13 virus-treated animals developed hepatocellular cancer. Immunohistochemical analysis revealed a mosaic of FAH-deficient and FAH-positive cells in all animals and liver function tests were improved compared to controls. Even mice harvested 9 months after viral infection had >50% FAH-positive cells. These results demonstrate the strong selective advantage of FAH-expressing cells in an FAH-deficient liver but also illustrate the danger of carcinomas arising from FAH-deficient hepatocytes in HT1. In this study, we tested the effectiveness of a fumarylacetoacetate hydrolase (FAH)-expressing adenovirus in the treatment of a mouse model of the human disease hereditary tyrosinemia type I (HT1). Thirteen mice were treated with the recombinant adenovirus and analyzed at intervals ranging from 2 to 9 months after injection. All treated mice had improved survival, weight gain, and liver function tests. A high percentage (>20%) of hepatic cells remained FAH-positive, even 6–9 months post injection. However, 9 of 13 mice developed either microscopic or macroscopic hepatocellular carcinomas originating from nontransduced FAH-negative cells. This report demonstrates that adenoviral gene therapy of HT1 is aided by the strong selective advantage of FAH-expressing cells, but also that adenoviral gene therapy does not obviate the tumor risk inherent in HT1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
LINDSTEDT, S. (1992) · The Lancet · doi:10.1016/0140-6736(92)92685-9 · Cited by 631 · cited 1×
“All breeders and all mutant animals were tteated with NTBC-containing drinking water at a concenttation of 7.6 mg/liter (Lindstedt et al., 1992; Grompe et al., 1995) Imme diately after injection, adenovims-injected animals and conttols were removed from N T BC treatment.”
InfluentialOverturf, K., Al-Dhalimy, M., Tanguay, R., Brantly, M., Ou, C.-N., Finegold, M., & Grompe, M. (1996) · Nature Genetics · doi:10.1038/ng0396-266 · Cited by 549
Self-citationGrompe, M., al-Dhalimy, M., Finegold, M., Ou, C. N., Burlingame, T., Kennaway, N. G., & Soriano, P. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2298 · Cited by 355 · cited 2×
“We used the Fah'^^"""' sttain mice as described (Grompe et al., 1993).”
Self-citationGrompe, M., Lindstedt, S., Al-Dhalimy, M., Kennaway, N. G., Papaconstantinou, J., Torres-Ramos, C. A., Ou, C.-N., & Finegold, M. (1995) · Nature Genetics · doi:10.1038/ng0895-453 · Cited by 312 · cited 4×
“…humans suffering with the disease Unfortanately, however even in NTBC-tteated animals, hepatic cancer arises as a late complication of the disease (Grompe et al., 1995) Liver ttansplantation is a successful therapy for HTl (Par adis et al., 1990; Murcia et al., 1995), and, therefore, the dis ease…”
InfluentialSelf-citationSelf-induced correction of the genetic defect in tyrosinemia type I.
Kvittingen, E. A., Rootwelt, H., Berger, R., & Brandtzaeg, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117509 · Cited by 168
Hereditary tyrosinemia type I: Self-induced correction of the fumarylacetoacetase defect
Kvittingen, E. A., Rootwelt, H., Brandtzaeg, P., Bergan, A., & Berger, R. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116393 · Cited by 102 · cited 1×
“- ?, ficient cells (Kvittingen et al, 1993, 1994; Overturf et al, 1996). in Recently, we have shown that this phenomenon can be exploited to cortect > 9 0% of parenchymal hepatocytes of F AH mutant mice by rettovttal gene therapy (Overturf et al, 1996).”
Cited by
The ploidy conveyor of mature hepatocytes as a source of genetic variation
Duncan, A. W., Taylor, M. H., Hickey, R. D., Hanlon Newell, A. E., Lenzi, M. L., Olson, S. B., Finegold, M. J., & Grompe, M. (2010) · Nature · doi:10.1038/nature09414 · Cited by 525
Self-citationLaconi, E., Oren, R., Mukhopadhyay, D. K., Hurston, E., Laconi, S., Pani, P., Dabeva, M. D., & Shafritz, D. A. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65574-5 · Cited by 381
Characterization of Adeno-Associated Virus Genomes Isolated from Human Tissues
Schnepp, B. C., Jensen, R. L., Chen, C.-L., Johnson, P. R., & Clark, K. R. (2005) · Journal of Virology · doi:10.1128/jvi.79.23.14793-14803.2005 · Cited by 231
“, naked plasmid DNA and adenovirus vectors) random integration of introduced DNA has been shown to occur (17, 34, 46, 47).”
BackgroundDe Vree, J. M. L., Ottenhoff, R., Bosma, P. J., Smith, A. J., Aten, J., & Oude Elferink, R. P. J. (2000) · Gastroenterology · doi:10.1053/gast.2000.20222 · Cited by 186
The pathophysiology and treatment of hereditary tyrosinemia type 1
Grompe, M. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-19035 · Cited by 167
Self-citation
Metadata
- Authors
- Overturf, K., Al-Dhalimy, M., Ou, C. N., Finegold, M., Tanguay, R., Lieber, A., Kay, M., & Grompe, M.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1997-03-20
- Volume
- 8
- Issue
- 5
- Pages
- 513-521
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2031631992
- Cited by
- 77
- References
- 6
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type I. https://app.cochat.ai/papers/10.1089/hum.1997.8.5-513
- The paper
- Overturf, K., Al-Dhalimy, M., Ou, C. N., Finegold, M., Tanguay, R., Lieber, A., Kay, M., & Grompe, M. (1997). Adenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type I. Human Gene Therapy. https://doi.org/10.1089/hum.1997.8.5-513
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.